Compare HRTG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | DCTH |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 578.4M |
| IPO Year | 2014 | 2015 |
| Metric | HRTG | DCTH |
|---|---|---|
| Price | $35.93 | $14.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $40.00 | $24.00 |
| AVG Volume (30 Days) | 189.1K | ★ 262.9K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | 107.53 |
| EPS | ★ 3.23 | 0.04 |
| Revenue | ★ $847,330,000.00 | N/A |
| Revenue This Year | $1.48 | $24.61 |
| Revenue Next Year | $3.18 | $24.27 |
| P/E Ratio | ★ $11.15 | $351.75 |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $20.48 | $8.12 |
| 52 Week High | $37.87 | $17.42 |
| Indicator | HRTG | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 42.11 |
| Support Level | $32.83 | $14.26 |
| Resistance Level | $37.87 | $16.51 |
| Average True Range (ATR) | 1.27 | 0.53 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 48.96 | 29.33 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.